Aurobindo Pharma’s consolidated net profit for the March quarter rose 2% to ₹921 crore compared to the ₹903 crore a year earlier.

Revenue from operations of the Hyderabad-headquartered generic drugmaker increased 5.6% to ₹8,853 crore (₹8,382 crore) even as U.S. formulations revenue declined 13 YoY to ₹3,543 crore primarily on account of lower transient sales. Bolstering the revenue were Europe and Growth markets. In Europe, Aurobindo Pharma registered 30.2% increase in revenue to ₹2,795 crore (₹2,147 crore); and more than 24.7% in Growth Markets to ₹980 crore (₹786 crore).

While total formulations revenue at ₹7,646 crore was an increase of 4.6%, total API sales was almost 13% more at ₹1,208 crore.

Vice-chairman and managing director K. Nithyananda Reddy said, “We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio. Consistent volumes coupled with improved operating efficiencies and disciplined execution have contributed positively to our results.”

For FY26, the net profit was flat at ₹3,503 crore (₹3,484 crore) on a 6.1% increase in revenue from operations to ₹33,653 crore (₹31,724 crore). The company said its European business crossed €1 billion in revenues during the fiscal.